4.2 Article

A renal metanephric adenoma showing both a 2p16-24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?

Journal

CANCER GENETICS
Volume 206, Issue 9-10, Pages 347-352

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cancergen.2013.09.002

Keywords

Metanephric adenoma; BRAF V600E mutation; chromosomal imbalance; tumor suppressor gene; short arm of chromosome 2

Funding

  1. French National Cancer Institute (Institut National du Cancer (INCa)

Ask authors/readers for more resources

Metanephric adenomas (MAs) are rare benign tumors that may be difficult to recognize. Specific genetic anomalies might aid in diagnosis, but genomic data are limited and conflicting. Consistent mutations of the BRAF gene have been recently reported in MAs and could become useful as a discriminative marker among renal tumors. We report here a case of MA, showing both a BRAF V600E mutation and a segmental loss within bands 2p16 and 2p24 as the sole quantitative genomic anomaly. We compared the borders and size of the deleted region in our case to those of five cases of MAs previously reported. We identified a common minimal region containing 87 genes, among which several tumor suppressor genes could be candidate actors in the pathogenesis of MA. We ruled out MSH2 and MSH6 as target gene candidates, both located in the deleted region, on the basis of preserved expression and microsatellite sequence stability. Our study confirms the recurrence of a BRAF mutation and of 2p alterations in MAs. This first case showing simultaneous presence of a BRAF mutation and a 2p deletion raises the question of a synergistic role for these two anomalies in the pathogenesis of MAs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Dermatology

Proliferating Onychomatricoma. Clinical, Dermoscopical, and Pathologic Features of Onychomatricoma New Variant Resembling Onycholemmal/Squamous Cell Carcinoma

Christophe Perrin, Damien Ambrosetti, Brigitte Balme, Luc Thomas

AMERICAN JOURNAL OF DERMATOPATHOLOGY (2020)

Article Neurosciences

Hypoxia and hypoxia-inducible factors promote the development of neointimal hyperplasia in arteriovenous fistula

Nirvana Sadaghianloo, Julie Contenti, Serge Declemy, Damien Ambrosetti, Masa Zdralevic, Mounia Tannour-Louet, Lucilla Fabbri, Gilles Pages, Frederic Bost, Reda Hassen-Khodja, Jacques Pouyssegur, Elixene Jean-Baptiste, Alan Dardik, Nathalie M. Mazure

Summary: Patients with end-stage renal failure need AVFs for dialysis, but these AVFs often fail due to excessive venous thickness. This study found that venous cells adapt their metabolism depending on oxygen concentration, and targeting the hypoxic response pathway with drugs can help decrease excessive venous thickness. In a mouse model, inhibiting HIFs decreased neointimal hyperplasia, suggesting that drugs targeting HIFs could prevent AVF failure.

JOURNAL OF PHYSIOLOGY-LONDON (2021)

Article Biology

Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma

Maeva Dufies, Annelies Verbiest, Lindsay S. Cooley, Papa Diogop Ndiaye, Xingkang He, Nicolas Nottet, Wilfried Souleyreau, Anais Hagege, Stephanie Torrino, Julien Parola, Sandy Giuliano, Delphine Borchiellini, Renaud Schiappa, Baharia Mograbi, Jessica Zucman-Rossi, Karim Bensalah, Alain Ravaud, Patrick Auberger, Andreas Bikfalvi, Emmanuel Chamorey, Nathalie Rioux-Leclercq, Nathalie M. Mazure, Benoit Beuselinck, Yihai Cao, Jean Christophe Bernhard, Damien Ambrosetti, Gilles Pages

Summary: Dufies et al. found high Plk1 expression levels in aggressive clear cell renal cell carcinoma and discovered that Plk1 is transcriptionally upregulated in a manner dependent on HIF-2. They also found that high Plk1 expression is correlated to a poor prognosis and resistance to tyrosine kinase inhibitor against VEGF receptor, suggesting a critical role for hypoxia/HIF-2-induced Plk1 in disease progression.

COMMUNICATIONS BIOLOGY (2021)

Article Urology & Nephrology

Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy

Damien Ambrosetti, Michael Coutts, Charlotte Paoli, Matthieu Durand, Delphine Borchiellini, Christopher Montemagno, Olivia Rastoin, Arnaud Borderie, Renaud Grepin, Nathalie Rioux-Leclercq, Jean-Christophe Bernhard, Gilles Pages, Maeva Dufies

Summary: The study found that VEGFR-TKI significantly increased the number of CAFs in tumors, which were associated with shorter disease-free and overall survival in patients. The presence of CAFs was also correlated with lymphangiogenesis and lymph node metastasis, and CAFs promoted cell migration while reducing the cytotoxic effect of VEGFR-TKI on tumor cells.

BJU INTERNATIONAL (2022)

Article Oncology

RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases

Ilaria Di Mauro, Berengere Dadone-Montaudie, Mathilde Sibony, Damien Ambrosetti, Vincent Molinie, Myriam Decaussin-Petrucci, Vincent Bland, Claire Arbaud, Beatrice Cenciu, Francois Arbib, Pierre-Alexandre Just, Jonathan Derman, Nathalie Rioux-Leclercq, Florence Pedeutour

Summary: Accurately diagnosing Xp11-translocation renal cell carcinoma (RCC) in adults can be challenging, with TFE3 fusion generally occurring with a partner gene on another chromosome but occasionally with neighboring gene RBM10. Despite the difficulty, it is crucial to molecularly detect RBM10-TFE3 fusion as it is not exceptional in adult cases and may require targeted RNA sequencing for confirmation. Additionally, investigating RCC with type-2 papillary features and 17q gain by RNASeq could be a valuable avenue for further research.

GENES CHROMOSOMES & CANCER (2021)

Article Urology & Nephrology

Active Surveillance for Biopsy Proven Renal Oncocytomas: Outcomes and Feasibility

Francois-Xavier Deledalle, Damien Ambrosetti, Mathieu Durand, Floriane Michel, Michael Baboudjian, Bastien Gondran-Tellier, Francois Lannes, Laurent Daniel, Marc Andre, Pierre-Olivier Fais, Pierre-Henri Savoie, Xavier Durand, Dominique Rossi, Gilles Karsenty, Cyrille Bastide, Eric Lechevallier, Romain Boissier

Summary: This study reported on the outcomes and feasibility of active surveillance of biopsy-proven renal oncocytomas. The results showed that active surveillance was oncologically safe with high patient adherence, low tumor growth rate, and high biopsy efficacy. No predictive factors for tumor growth could be identified.

UROLOGY (2021)

Article Dermatology

Pleomorphic Onychomatricoma: A Mimicker of Malignancy

Christophe Perrin, Damien Ambrosetti

Summary: This study characterizes the features and diagnostic criteria of pleomorphic onychomatricoma, a rare condition that mimics malignant neoplasms.

ACTA DERMATO-VENEREOLOGICA (2022)

Article Biochemistry & Molecular Biology

Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression

Lindsay S. Cooley, Justine Rudewicz, Wilfried Souleyreau, Andrea Emanuelli, Arturo Alvarez-Arenas, Kim Clarke, Francesco Falciani, Maeva Dufies, Diether Lambrechts, Elodie Modave, Domitille Chalopin-Fillot, Raphael Pineau, Damien Ambrosetti, Jean-Christophe Bernhard, Alain Ravaud, Sylvie Negrier, Jean-Marc Ferrero, Gilles Pages, Sebastien Benzekry, Macha Nikolski, Andreas Bikfalvi

Summary: By serially passaging mouse renal cancer cells in vivo, researchers generated multiple cell lines with varying aggressiveness and identified distinct molecular markers and gene processes associated with different stages of tumor progression using transcriptome, genome and methylome analyses. Specific biomarkers such as SAA2 and CFB were identified as soluble prognostic and predictive markers of therapeutic response, with machine learning and mathematical modeling highlighting their significant impact on distant metastasis-free survival. A computational model predicting tumor progression and relapse was developed and validated, providing important translational implications for RCC therapy.

MOLECULAR CANCER (2021)

Article Cell Biology

Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression

Solene-Florence Kammerer-Jacquet, Camille Gandon, Frederic Dugay, Brigitte Laguerre, Benoit Peyronnet, Romain Mathieu, Gregory Verhoest, Karim Bensalah, Xavier Leroy, Sebastien Aubert, Catherine Vermaut, Fabienne Escande, Virginie Verkarre, Eva Comperat, Damien Ambrosetti, Florence Pedeutour, Marc-Antoine Belaud-Rotureau, Nathalie Rioux-Leclercq

Summary: This study reports the clinical, histological, immunohistochemical, and genetic features of nine cases of renal cell carcinoma with TFEB amplification. The diagnosis of this rare molecular subgroup is confirmed by FISH analysis, and CGH analysis reveals complex genomic alterations. The prognosis is poor, and combination therapy might be beneficial for these aggressive tumors.

HISTOPATHOLOGY (2022)

Letter Cell Biology

Tinea corporis with misleading clinical and histologic features of lymphomatoid papulosis

Christophe Perrin, Giorgio Toni, Michael Coutts, Damien Ambrosetti

HISTOPATHOLOGY (2022)

Review Biochemistry & Molecular Biology

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights

Audrey Simonaggio, Damien Ambrosetti, Virginie Verkarre, Marie Auvray, Stephane Oudard, Yann-Alexandre Vano

Summary: MiTF/TFE translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of RCC, which is more prevalent in the pediatric population and represents 4% of all RCCs in adults. The diagnosis of tRCC involves translocations of genes such as TFE3, TFEB or MITF. TFE break-apart fluorescent in situ hybridization (FISH) is considered the gold standard for diagnosis. tRCC exhibits heterogeneous clinical behaviors and is more aggressive in adults. Effective treatment options for metastatic tRCC are limited, highlighting the need for better therapeutic approaches. Comprehensive genetic sequencing analyses have provided insights into the biological heterogeneity of tRCC, aiding in the development of more effective treatments.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Urology & Nephrology

Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15)

Astrid Boulenger de Hauteclocque, Loic Ferrer, Damien Ambrosetti, Solene Ricard, Pierre Bigot, Karim Bensalah, Francois Henon, Nicolas Doumerc, Arnaud Mejean, Virginie Verkarre, Charles Dariane, Stephane Larre, Cecile Champy, Alexandre de La Taille, Franck Bruyere, Morgan Roupret, Philippe Paparel, Stephane Droupy, Alexis Fontenil, Jean-Jacques Patard, Xavier Durand, Thibaut Waeckel, Herve Lang, Cedric Lebacle, Laurent Guy, Geraldine Pignot, Matthieu Durand, Jean-Alexandre Long, Thomas Charles, Evanguelos Xylinas, Romain Boissier, Mokrane Yacoub, Thierry Colin, Jean-Christophe Bernhard

Summary: This study assessed the impact of pathological upstaging in renal cell carcinoma patients and evaluated the oncological safety of different surgical approaches. A machine-learning model was developed to predict upstaging. The findings showed that machine-learning technology can be useful in evaluating and predicting upstaging in renal cell carcinoma. Partial nephrectomy did not compromise oncological outcomes in incidental upstaging, even for large tumors.

BJU INTERNATIONAL (2023)

Review Urology & Nephrology

Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis

Michael Baboudjian, Daniel Moser, Takafumi Yanagisawa, Bastien Gondran-Tellier, Eva M. Comperat, Damien Ambrosetti, Laurent Daniel, Cyrille Bastide, Shahrokh F. Shariat, Eric Lechevallier, Pietro Diana, Alberto Breda, Benjamin Pradere, Romain Boissier

Summary: Active surveillance of biopsy-proven renal oncocytomas shows a low tumor growth rate, with oncological safety and good patient compliance. AS may represent a promising alternative to immediate treatment. Further studies on the long-term outcomes of AS are needed.

EUROPEAN UROLOGY OPEN SCIENCE (2022)

Proceedings Paper Cardiac & Cardiovascular Systems

Renal Cell Carcinoma Classification from Vascular Morphology

Rudan Xiao, Eric Debreuve, Damien Ambrosetti, Xavier Descombes

Summary: This study investigates the importance of vascular network structure in RCC diagnosis, and builds a dataset and features to demonstrate the role of vascular networks in RCC histopathological images.

MEDICAL IMAGE COMPUTING AND COMPUTER ASSISTED INTERVENTION - MICCAI 2021, PT VI (2021)

Article Medicine, Research & Experimental

The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy

Anais Hagege, Damien Ambrosetti, Julien Boyer, Alexandre Bozec, Jerome Doyen, Emmanuel Chamorey, Xingkang He, Isabelle Bourget, Julie Rousset, Esma Saada, Olivia Rastoin, Julien Parola, Frederic Luciano, Yihai Cao, Gilles Pages, Maeva Dufies

Summary: High expression of Plk1 is associated with poor prognosis in HNSCC, while onvansertib shows potential therapeutic effects by inducing apoptosis. Combination of onvansertib with cisplatin and/or radiotherapy synergistically induces tumor cell death.

THERANOSTICS (2021)

No Data Available